Last reviewed · How we verify
NCT07345247: RASEREM
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study
trial in Liver Cancer, Adult in 150 participants. Currently enrolling.
1 March 2028
Quick facts
| Lead sponsor | Ankara University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 August 2025 |
| Primary completion | 1 March 2028 |
| Estimated completion | 1 August 2028 |
| Sites | 20 locations across Turkey (Türkiye) |
Conditions studied
- Liver Cancer, Adult — all drugs for Liver Cancer, Adult →
Sponsor
Ankara University
Who can join
18 and older, any sex, with Liver Cancer, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radiation segmentectomy (RS) refers to selective infusion of Y-90 microspheres to the tumor bearing hepatic segment of hepatic artery. Majority of the data on RS is based on the Glass microspheres experience. Due to different properties of Resin and Glass microspheres description of dose limits to the segment for effectiveness of treatments with Resin microspheres are needed. Based on this background in this study it is aimed to evaluate the safety and efficacy of RS with resin microspheres in HCC patients. Secondly, it is planned to describe the dose limits for complete radiological response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07345247
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cancer, Adult
Currently open trials in the same condition.
- NCT07295262 — NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC · EARLY_PHASE1 · recruiting
- NCT07315633 — An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies fo · recruiting
- NCT06689540 — Mts105 for Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
- NCT07070362 — Digital Early Warning System for Acute Lung Injury in Liver Surgery · recruiting
- NCT06777628 — Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma · recruiting
Other Ankara University trials
Trials by the same sponsor.
- NCT07441837 — Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients · Phase 2 · not yet recruiting
- NCT07536490 — Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease · not yet recruiting
- NCT06959433 — Lu-177 PSMA Treatment in Cell Renal Carcinoma · Phase 3 · not yet recruiting
- NCT07513272 — EFFECT OF BALLS ON PAIN AND ANXIETY DURING VENIPUNCTURE IN CHILDREN · NA · not yet recruiting
- NCT07536542 — Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07345247 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara University
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07345247.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing